We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis

Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing innovative drugs to treat Idiopathic Pulmonary Fibrosis.  

Both parties will contribute scientifically, with Aptuit providing integrated early Discovery capabilities, including Medicinal Chemistry and Pharmacology, as well as Drug Metabolism and Pharmacokinetics, in order to identify promising compounds for further pre-clinical development. 

Dr. Jonathan Goldman, Chief Executive Officer, Aptuit, stated, “This project builds upon the existing relationship between Chiesi and Aptuit in the field of Respiratory Drug Discovery. We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease”.  

Dr. Mark Parry Billings, Corporate Drug Development Head, Chiesi Farmaceutici, commented, “We are very pleased to announce the partnership with Aptuit.  We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow our Project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in Respiratory drug discovery”.

Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.